{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T10:42:40Z","timestamp":1784025760450,"version":"3.55.0"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T00:00:00Z","timestamp":1578873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,2,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>Evidence on the use of antithrombotic pharmacotherapy in patients undergoing revascularization of lower extremities for symptomatic peripheral arterial disease (PAD) is reviewed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>Individuals with PAD can experience leg pain, intermittent claudication, critical limb ischemia, and acute limb ischemia. In such patients, revascularization may be indicated to improve the quality of life and to prevent amputations. Antithrombotic therapy is often intensified in the postrevascularization period to prevent restenosis of the index artery and to counteract the prothrombotic state induced by the intervention. Therapeutic modalities include dual antiplatelet therapy (DAPT), anticoagulation, a combination of antiplatelet and anticoagulation therapy, and addition of cilostazol to single antiplatelet therapy. Subgroup analyses of data from randomized clinical trials provided low-quality evidence for the use of DAPT in patients with a below-knee prosthetic bypass graft and anticoagulation for those with a venous bypass graft. Cilostazol, when added to aspirin therapy, has been shown to prevent index vessel reocclusion after an endovascular intervention in patients at low risk for thrombosis in several small randomized trials.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>There is a considerable paucity of high-quality evidence on the optimal antithrombotic regimen for patients undergoing lower extremity revascularization, with no particular therapy shown to consistently improve patient outcomes. The decision to initiate intensified antithrombotic therapy should include a close examination of its risk\u2013benefit profile. The demonstrated benefit of such treatment is restricted to the prevention of index artery reocclusion, while an increased risk of bleeding may lead to significant morbidity and mortality.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxz315","type":"journal-article","created":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T02:46:47Z","timestamp":1578883607000},"page":"269-276","source":"Crossref","is-referenced-by-count":9,"title":["Antithrombotic therapy for postinterventional management of peripheral arterial disease"],"prefix":"10.1093","volume":"77","author":[{"given":"Daria","family":"Zavgorodnyaya","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara B","family":"Knight","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Dell Seton Medical Center at the University of Texas, Ascension Seton, Austin, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell J","family":"Daley","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Dell Seton Medical Center at the University of Texas, Ascension Seton, Austin, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro G","family":"Teixeira","sequence":"additional","affiliation":[{"name":"Department of Surgery and Perioperative Care, Dell Medical School, the University of Texas at Austin, Austin, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,1,13]]},"reference":[{"key":"2020020707430273300_CIT0001","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMcp1507631","article-title":"Peripheral artery disease","volume":"374","author":"Kullo","year":"2016","journal-title":"N Engl J Med"},{"key":"2020020707430273300_CIT0002","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.amepre.2006.12.010","article-title":"Ethnic-specific prevalence of peripheral arterial disease in the United States","volume":"32","author":"Allison","year":"2007","journal-title":"Am J Prev Med."},{"key":"2020020707430273300_CIT0003","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ejvs.2015.10.022","article-title":"The risk of disease progression in peripheral arterial disease is higher than expected: a meta-analysis of mortality and disease progression in peripheral arterial disease","volume":"51","author":"Sigvant","year":"2016","journal-title":"Eur J Vasc Endovasc Surg."},{"key":"2020020707430273300_CIT0004","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.jacc.2016.11.008","article-title":"2016 AHA\/ACC guideline on the management of patients with lower extremity peripheral artery disease: executive summary","volume":"69","author":"Gerhard-Herman","year":"2017","journal-title":"J Am Coll Cardiol."},{"key":"2020020707430273300_CIT0005","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","article-title":"2017 ESC Guidelines on the diagnosis and treatment of peripheral arterial disease, in collaboration with the European Society of Vascular Surgery (ESVS)","volume":"39","author":"Aboyans","year":"2018","journal-title":"Eur Heart J"},{"key":"2020020707430273300_CIT0006","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.jacc.2007.10.034","article-title":"The problem with composite end points in cardiovascular studies: the story of major adverse cardiac events and percutaneous coronary intervention","volume":"51","author":"Kip","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2020020707430273300_CIT0007","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1001\/jama.286.13.1599","article-title":"Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment","volume":"286","author":"McDermott","year":"2001","journal-title":"JAMA."},{"key":"2020020707430273300_CIT0008","doi-asserted-by":"crossref","first-page":"2S","DOI":"10.1016\/j.jvs.2014.12.009","article-title":"Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication","volume":"61","author":"Conte","year":"2015","journal-title":"J Vasc Surg."},{"key":"2020020707430273300_CIT0009","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.jvs.2006.12.037","article-title":"Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)","volume":"45","author":"Norgen","year":"2007","journal-title":"J Vasc Surg."},{"key":"2020020707430273300_CIT0010","doi-asserted-by":"crossref","first-page":"e162024","DOI":"10.1001\/jamasurg.2016.2024","article-title":"Effectiveness of a medical vs revascularization intervention for intermittent leg claudication based on patient-reported outcomes","volume":"151","author":"Devine","year":"2016","journal-title":"JAMA Surg."},{"key":"2020020707430273300_CIT0011","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1161\/CIRCULATIONAHA.114.009867","article-title":"Improved quality of life after 1 year with an invasive versus a noninvasive treatment strategy in claudicants: one-year results of the Invasive Revascularization or Not in Intermittent Claudication (IRONIC) Trial","volume":"130","author":"Nordanstig","year":"2014","journal-title":"Circulation."},{"key":"2020020707430273300_CIT0012","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-019-02166-0","article-title":"Comparison of three generic quality-of-life metrics in peripheral arterial disease patients undergoing conservative and invasive treatments","author":"Petersohn","year":"2019","journal-title":"Qual Life Res"},{"key":"2020020707430273300_CIT0013","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1161\/CIRCULATIONAHA.113.001560","article-title":"Management of patients after endovascular interventions for peripheral artery disease","volume":"128","author":"Sobieszczyk","year":"2013","journal-title":"Circulation."},{"key":"2020020707430273300_CIT0014","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1161\/CIRCULATIONAHA.112.001232","article-title":"Outcomes for clinical studies assessing drug and revascularization therapies for claudication and critical limb ischemia in peripheral artery disease","volume":"127","author":"Kenlay","year":"2013","journal-title":"Circulation"},{"key":"2020020707430273300_CIT0015","first-page":"577","article-title":"Graft thrombosis","author":"Suckow"},{"key":"2020020707430273300_CIT0016","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.jvs.2009.09.044","article-title":"Suggested objective performance goals and clinical trial design for evaluating catheter-based treatment of critical limb ischemia","volume":"50","author":"Conte","year":"2009","journal-title":"J Vasc Surg."},{"key":"2020020707430273300_CIT0017","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jvs.2016.02.059","article-title":"Predictive factors for better bypass patency and limb salvage after prosthetic above-knee bypass reconstruction","volume":"64","author":"Klingelhoefer","year":"2016","journal-title":"J Vasc Surg"},{"key":"2020020707430273300_CIT0018","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.jvir.2012.11.020","article-title":"Failure of surgical and endovascular infrainguinal and iliac procedures in the management of peripheral arterial disease using data from electronic medical records","volume":"24","author":"Sussman","year":"2013","journal-title":"J Vasc Interv Radiol"},{"key":"2020020707430273300_CIT0019","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/j.jvs.2015.06.228","article-title":"Objective performance goals after endovascular intervention for critical limb ischemia","volume":"62","author":"Davies","year":"2015","journal-title":"J Vasc Surg."},{"key":"2020020707430273300_CIT0020","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.jcin.2015.07.005","article-title":"3-year outcomes of the OLIVE registry, a prospective multicenter study of patients with critical limb ischemia: a prospective, multi-center, three-year follow-up study on endovascular treatment for infra-inguinal vessel in patients with critical limb ischemia","volume":"8","author":"Iida","year":"2015","journal-title":"JACC Cardiovasc Interv"},{"key":"2020020707430273300_CIT0021","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1053\/ejvs.2000.1125","article-title":"Risk factors for occlusion of infrainguinal bypass grafts","volume":"202","author":"Tangelder","year":"2000","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"2020020707430273300_CIT0022","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/j.jvs.2018.06.193","article-title":"Major adverse limb events and major adverse cardiac events after contemporary lower extremity bypass and infrainguinal endovascular intervention in patients with claudication","volume":"68","author":"Fashandi","year":"2018","journal-title":"J Vasc Surg."},{"key":"2020020707430273300_CIT0023","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.jvs.2018.03.413","article-title":"Lower extremity bypass and endovascular intervention for critical limb ischemia fail to meet Society for Vascular Surgery\u2019s objective performance goals for limb-related outcomes in a contemporary national cohort","volume":"68","author":"Robinson","year":"2018","journal-title":"J Vasc Surg."},{"key":"2020020707430273300_CIT0024","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ahj.2015.04.026","article-title":"Anatomic runoff score predicts cardiovascular outcomes in patients with lower extremity peripheral artery disease undergoing revascularization","volume":"170","author":"Jones","year":"2015","journal-title":"Am Heart J"},{"key":"2020020707430273300_CIT0025","doi-asserted-by":"publisher","first-page":"CD002071","DOI":"10.1002\/14651858.CD002071.pub3","article-title":"Antiplatelet and anticoagulant drugs for prevention of restenosis\/reocclusion following peripheral endovascular treatment","volume":"8","author":"Robertson","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"2020020707430273300_CIT0026","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1177\/000331979004100402","article-title":"Reocclusion prophylaxis with dipyridamole combined with acetylsalicylic acid following PTA","volume":"41","author":"Heiss","year":"1990","journal-title":"Angiology"},{"key":"2020020707430273300_CIT0027","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1161\/01.CIR.91.8.2167","article-title":"Comparison of effects of high-dose and low-dose aspirin on restenosis after femoropopliteal percutaneous transluminal angioplasty","volume":"91","author":"Minar","year":"1995","journal-title":"Circulation"},{"key":"2020020707430273300_CIT0028","first-page":"A74","article-title":"Controlled trial of high versus low dose aspirin treatment after PTA in patients with peripheral vascular disease","volume":"68","author":"Creutzig","year":"1994","journal-title":"Ann Hematol."},{"key":"2020020707430273300_CIT0029","first-page":"57","article-title":"Acetylsalicylic acid\u2013reocclusion\u2013prophylaxis after angioplasty (ARPA-study). A randomized double-blind trial of two different dosages of ASA in patients with peripheral occlusive arterial disease","volume":"23","author":"Weichert","year":"1994","journal-title":"Vasa."},{"key":"2020020707430273300_CIT0030","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1583\/13-4275MR.1","article-title":"Twelve-month results of a randomized trial comparing mono with dual antiplatelet therapy in endovascularly treated patients with peripheral artery disease","volume":"20","author":"Strobl","year":"2013","journal-title":"J Endovasc Ther"},{"key":"2020020707430273300_CIT0031","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1177\/1526602818760488","article-title":"Edoxaban plus aspirin vs dual antiplatelet therapy in endovascular treatment of patients with peripheral artery disease: results of the ePAD trial","volume":"25","author":"Moll","year":"2018","journal-title":"J Endovasc Ther."},{"key":"2020020707430273300_CIT0032","author":"ClinicalTrials.gov"},{"key":"2020020707430273300_CIT0033","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jvs.2008.02.062","article-title":"Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions","volume":"48","author":"Iida","year":"2008","journal-title":"J Vasc Surg"},{"key":"2020020707430273300_CIT0034","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jacc.2008.09.020","article-title":"Efficacy of cilostazol after endovascular therapy for femoropopliteal artery disease in patients with intermittent claudication","volume":"53","author":"Soga","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2020020707430273300_CIT0035","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1161\/CIRCULATIONAHA.112.000711","article-title":"Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study","volume":"127","author":"Iida","year":"2013","journal-title":"Circulation"},{"key":"2020020707430273300_CIT0036","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.avsg.2017.05.029","article-title":"Efficacy of cilostazol for Below-the-Knee Artery Disease after Balloon angioplasty in patients with Severe Limb Ischemia (CABBAGE Trial)","volume":"45","author":"Soga","year":"2017","journal-title":"Ann Vasc Surg."},{"key":"2020020707430273300_CIT0037","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1161\/CIR.0000000000000426","article-title":"Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association","volume":"134","author":"Page","year":"2016","journal-title":"Circulation."},{"key":"2020020707430273300_CIT0038","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1540-8175.2010.01357.x","article-title":"Impact of cilostazol on left ventricular geometry and function: assessment by tissue Doppler imaging and two-dimensional speckle-tracking echocardiography","volume":"28","author":"Yoshikawa","year":"2011","journal-title":"Echocardiography"},{"key":"2020020707430273300_CIT0039","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.jvs.2010.04.027","article-title":"Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial","volume":"52","author":"Belch","year":"2010","journal-title":"J Vasc Surg"},{"key":"2020020707430273300_CIT0040","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0140-6736(99)07199-8","article-title":"Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral Anticoagulants or Aspirin Study): a randomised trial","volume":"355","author":"The Dutch Bypass Oral anticoagulants or Aspirin (BOA) Study Group","year":"2000","journal-title":"Lancet."},{"key":"2020020707430273300_CIT0041","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S0741-5214(98)70130-2","article-title":"Warfarin improves the outcome of infrainguinal vein bypass grafting at high risk for failure","volume":"28","author":"Sarac","year":"1998","journal-title":"J Vasc Surg"},{"key":"2020020707430273300_CIT0042","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1067\/mva.2002.121847","article-title":"Benefits, morbidity, and mortality associated with long-term administration of oral anticoagulant therapy to patients with peripheral arterial bypass procedures: a prospective randomized study","volume":"35","author":"Johnson","year":"2002","journal-title":"J Vasc Surg."},{"key":"2020020707430273300_CIT0043","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jvs.2012.01.004","article-title":"Combination therapy with warfarin plus clopidogrel improves outcomes in femoropopliteal bypass surgery patients","volume":"56","author":"Monaco","year":"2012","journal-title":"J Vasc Surg"},{"key":"2020020707430273300_CIT0044","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejvs.2004.11.011","article-title":"Effects of three months of low molecular weight heparin (dalteparin) treatment after bypass surgery for lower limb ischemia\u2014a randomised placebo-controlled double blind multicentre trial","volume":"29","author":"Jiveg\u00e5rd","year":"2005","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"2020020707430273300_CIT0045","doi-asserted-by":"crossref","first-page":"e669S","DOI":"10.1378\/chest.11-2307","article-title":"Antithrombotic therapy in peripheral artery disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Alonso-Coello","year":"2012","journal-title":"Chest"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/77\/4\/269\/32373323\/zxz315.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/77\/4\/269\/32373323\/zxz315.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T12:43:16Z","timestamp":1581079396000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/77\/4\/269\/5700877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,13]]},"references-count":45,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,1,13]]},"published-print":{"date-parts":[[2020,2,7]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxz315","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,2,15]]},"published":{"date-parts":[[2020,1,13]]}}}